Lamivudine

The current paper was a shot to style a sustained unharness dosage kind victimisation varied grades of hydrophilic polymers, Hypromellose or Hydroxy- propyl alkyl radical polysaccharide (HPMC K15M, HPMC K100M) and Chitosan additionally incorporated as rate retarding material. Laboratory scale batches of Six tablet formulations were ready by wet granulation technique (Low shear). Micromeritic properties of the granules were evaluated before compression. Tablets were characterized as crushing strength, friability, weight variation, thickness, Drug content or assay and evaluated for in-vitro unharness pattern for fifteen unit of time victimisation Phosphate buffer of suitable pH at 37±0.5°C. Results and discussion: The results obtained discovered that HPMC K15M, Chitosan and Ethylcellulose at an acceptable concentration formulation (F6) was able to sustain the drug unharness for fifteen hours and followed Higuchi pattern similar Fickian diffusion. moreover production validation scale batches were designed supported laboratory scale best batch and charged for stability testing. it had been found that every one parameters were at intervals the limit of acceptance. There was no chemical interaction found between the drug and excipients throughout FT-IR and DSC study thought of in the present investigation. therefore it may be over that combinely polymers at an acceptable concentration will effectively be formulate to sustain the drug unharness.

The aim of present research work was in-vitro evaluation of lamivudine extended release matrix tablets formulated by Eudragit S-100 and Eudragit L-100. FTIR studies shows that no chemical interactions were found. Physical mixture was evaluated for bulk density, tapped density, compressibility index, Hausner’s ratio and angle of repose before being punched as tablets. Various formulations of extended release matrix tablets of Lamivudine were prepared by different ratios of Eudragit S-100 and Eudragit L-100 by direct compression method with the rato of 16.66, 25.3 and 33. 3 % weight of both eudragit S-100 and eudragit L-100 were according to the total weight of tablet such formulations F1 to F6 and F7 to F9 both the polymers were taken as a combination F7 contains 8.33 % of eudragit s-100 and 8.33 % of eudragit L-100 similarly F8 and F9 also.. The tablets were evaluated for physical characterization.  From in-vitro dissolution studies all the formulations were analyzed and for the optimized formulation (F6) drug release was found to be 98% in 24hr with first order kinetics. The n values for the optimized F6 formulation was 0.620 which follows case II non-Fickian (anomalous) release (0.5≤ n ≤ 0.89). In the non-Fickian (anomalous) case II release, the rate of drug release is due to the combined effect of drug diffusion and polymer relaxation. Super Case II release generally refers to the polymer relaxation.